AMGN · 10-Q · 2026Q2 · Full report
Trade Policy and Tariffs
AMGEN INC · 2026-08-05 · Importance 40 · Surprise 42 · In source text
The United States and other countries have proposed or implemented numerous tariffs and trade-protection measures, including potential sector-specific tariffs on pharmaceuticals. In April 2026, the U.S. Administration imposed Section 232 tariffs on certain patented pharmaceuticals and associated active pharmaceutical ingredients. Amgen received relief from Section 232 tariffs for approximately three years from December 2025, citing its capital investments in U.S. manufacturing. Despite that relief, the company warns that tariffs and trade measures could adversely affect its business and results of operations.
Key facts
- Amgen received relief from Section 232 tariffs for approximately the next three years from December 2025 in recognition of its capital investments in U.S. manufacturing. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | committed | — | Amgen received relief from Section 232 tariffs for approximately the next three years from December 2025 in recognition of its capital… |
| cash | positive | committed | — | Amgen received relief from Section 232 tariffs for approximately the next three years from December 2025 in recognition of its capital… |